Similar articles

• Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure.

  Tougaard L, Sorensen E, Brochner-Mortensen J, Christensen MS, Rodbro P, Sorensen AW. Tougaard L, et al. Lancet. 1976 May 15;1(7968):1044-7. doi: 10.1016/s0140-6736(76)92220-0. Lancet. 1976. PMID: 57451 Clinical Trial.
• Effect of low dose 1 alpha-hydroxycholecalciferol on glomerular filtration rate in moderate renal failure.

  Eke FU, Winterborn MH. Eke FU, et al. Arch Dis Child. 1983 Oct;58(10):810-3. doi: 10.1136/adc.58.10.810. Arch Dis Child. 1983. PMID: 6357106 Free PMC article. Clinical Trial.
• Effects of 25-hydroxycholecalciferol on calcium metabolism in chronic renal failure.

  Letteri JM, Kleinman LM, Ellis KN, Caselnova R, Akhtar M, Cohn SH. Letteri JM, et al. Adv Exp Med Biol. 1977;81:591-601. doi: 10.1007/978-1-4613-4217-5_57. Adv Exp Med Biol. 1977. PMID: 899943 No abstract available.
• Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.

  Massry SG, Goldstein DA, Malluche HH. Massry SG, et al. Kidney Int. 1980 Oct;18(4):409-18. doi: 10.1038/ki.1980.154. Kidney Int. 1980. PMID: 7014981 Review. No abstract available.
• Pathogenesis of renal osteodystrophy: roles of phosphate and skeletal resistance to PTH.

  Ritz E, Malluche HH, Krempien B, Tschope W, Massry SG. Ritz E, et al. Adv Exp Med Biol. 1978;103:423-36. doi: 10.1007/978-1-4684-7758-0_44. Adv Exp Med Biol. 1978. PMID: 362849 Review. No abstract available.